Circ_0091702 relieves lipopolysaccharide (LPS)-induced cell injury by regulating the miR-182/PDE7A axis in sepsis

被引:9
|
作者
Zhang, Xinliang [1 ]
Dong, Shimin [1 ]
机构
[1] Hebei Med Univ, Dept Emergency, Hosp 3, Shijiazhuang, Hebei, Peoples R China
关键词
sepsis; cell injury; circ_0091702; miR-182; PDE7A; THERAPEUTIC TARGET; RNA; HYPOTHESIS;
D O I
10.1093/bbb/zbab100
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Circular RNA plays an important role in the progression of sepsis. Circ_0091702 has been found to be an important regulator of sepsis progression, so its role and mechanism in sepsis progression deserve to be further explored. Lipopolysaccharide (LPS) could suppress cell viability, while enhance cell apoptosis and inflammation to induce cell injury. Circ_0091702 was downregulated in LPS-induced HK2 cells, and its overexpression alleviated LPS-induced cell injury. MiR-182 could be sponged by circ_0091702. Moreover, miR-182 inhibitor could relieve LPS-induced cell injury, and its overexpression also reversed the inhibition of circ_0091702 on LPS-induced cell injury. PDE7A was a target of miR-182, and its expression was reduced in LPS-induced HK2 cells. Additionally, silencing of PDE7A reversed the suppressive effect of circ_0091702 on LPS-induced cell injury. Our data suggested that circ_0091702 sponged miR-182 to regulate PDE7A, thereby alleviating LPS-induced cell injury in sepsis.
引用
收藏
页码:1962 / 1970
页数:9
相关论文
共 42 条
  • [41] Long non-coding RNA (lncRNA) cancer susceptibility candidate 7 (CASC7) contributes to the progression of lipopolysaccharide (LPS)-induced liver injury by targeting microRNA-217(miR217)/toll-like receptor 4 (TLR4) axis
    Sun, Chengqin
    Chen, Yan
    Chen, Zhonge
    Wang, He
    Yang, Weiwen
    Zhou, Xiaoqian
    BIOMOLECULES AND BIOMEDICINE, 2024,
  • [42] Silencing of Long Non-coding RNA H19 Alleviates Lipopoly-saccharide (LPS)-induced Apoptosis and Inflammation Injury by Regulating miR-140-5p/TLR4 Axis in Cell Models of Pneumonia
    Yang, Hong
    CURRENT MOLECULAR MEDICINE, 2023, 23 (03) : 275 - 284